+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032- Product Image
Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032- Product Image
Sale

Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117479
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pre-Exposure Prophylaxis Market is projected to reach USD 2.04 Billion in 2026. It is expected to continue growing at a CAGR of 7.44%, reaching USD 3.18 Billion by 2032.

Pre-Exposure Prophylaxis: Executive Summary

Pre-exposure prophylaxis (PrEP) is a proven HIV prevention approach for people who do not have HIV but may face exposure. It can be delivered through oral medicines and, where authorized and available, long-acting injectable options. Its public-health value depends on accurate risk assessment, access to testing, clinical follow-up, adherence support, and integration with broader sexual-health services.

Prevention Is Shifting Toward Choice and Integration

The PrEP landscape is moving from a single-product model toward differentiated prevention, with daily oral regimens, event-driven use where clinically appropriate, and long-acting delivery options expanding the range of choices. Implementation is also shifting toward person-centered services, including community-led delivery, telehealth, streamlined testing, and integration with contraception, sexually transmitted infection care, and harm-reduction programs. Persistent barriers include stigma, uneven provider knowledge, regulatory differences, affordability, supply continuity, and limited access to routine monitoring.

Artificial Intelligence Can Strengthen the Care Pathway

Artificial intelligence can support PrEP programs by identifying service gaps, improving appointment and refill reminders, translating educational materials, and helping clinicians organize laboratory and adherence information. It may also assist public-health teams in targeting outreach while protecting confidentiality. These benefits depend on representative data, human oversight, transparent validation, cybersecurity, and safeguards against discriminatory risk scoring. AI should augment-not replace-clinical judgment, informed consent, and community participation.

Regional Insights Across Diverse Delivery Environments

North America combines established clinical infrastructure with continuing disparities linked to insurance, geography, stigma, and marginalized populations. Latin America is strengthening prevention access through public-health and community-based programs, while affordability and regulatory variation remain important considerations. Europe benefits from strong health systems and prevention networks, yet access differs across countries and populations. The Middle East requires culturally responsive services and careful attention to confidentiality. Africa carries a major share of global HIV prevention needs, making community delivery, task sharing, and reliable supply systems central. Asia-Pacific presents diverse regulatory and health-system contexts, with urban innovation coexisting with gaps in rural and underserved access.

Group-Level Priorities Shape Implementation

ASEAN countries face varied legal, financing, and service-delivery conditions, creating a need for adaptable regional cooperation. BRICS members represent large and diverse populations, where domestic manufacturing, public procurement, and differentiated delivery can influence access. The European Union can benefit from coordinated standards while retaining country-level flexibility. G7 systems generally have mature research and clinical capacity but must address inequities and prevention fatigue. GCC countries can strengthen confidential, integrated services within centralized health systems. NATO members span differing epidemics and health infrastructures, making interoperability, migrant access, and evidence-based prevention communication important shared priorities.

Country Context Requires Tailored Strategies

Australia has strong public-health and community-sector capability, with equity and rural access remaining relevant. Brazil’s combination of public provision and community engagement supports broad prevention efforts. Canada must navigate geographic distance, Indigenous health inequities, and jurisdictional variation. China’s large health system and evolving prevention services require scalable, confidential delivery. France, Germany, Italy, and Spain have substantial clinical capacity but continue to address awareness, stigma, and differences in access across regions and populations. India requires approaches suited to a large, diverse population and varied state-level systems. Japan and South Korea can expand awareness and culturally responsive access while addressing stigma. Mexico’s prevention programs benefit from stronger linkage between community services and public care. Russia’s response is shaped by regulatory, epidemiological, and service-access conditions. The United Kingdom has established sexual-health infrastructure, with local capacity and equitable access remaining priorities. The United States combines extensive clinical innovation with persistent disparities related to coverage, geography, and social determinants.

Leadership Priorities for Effective PrEP Programs

Industry and health-system leaders should prioritize a differentiated prevention portfolio that gives eligible people practical choices and clear counseling. They should strengthen routine HIV and renal monitoring, improve linkage from testing to prevention, and use community partnerships to reach populations underserved by conventional clinics. Supply resilience requires diversified procurement, transparent quality standards, and contingency planning. Programs should measure initiation, continuation, persistence, safety, patient experience, and equity-not only prescriptions or clinic visits. Digital and AI-enabled tools should undergo privacy, bias, and clinical-safety review before deployment, with affected communities involved in design and evaluation.

Methodology for a Reliable Executive View

This summary uses the supplied market topic as a scope definition and synthesizes established evidence from authoritative public-health guidance, peer-reviewed clinical research, regulatory information, and implementation literature. Findings are organized across delivery models, technology, geography, population groupings, and country contexts. The analysis emphasizes verified qualitative insights and excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Because policies and authorizations change, operational decisions should be checked against current national guidance and local clinical requirements.

Conclusion: Make Prevention Choice Accessible

PrEP is most effective as part of a convenient, trusted, and equitable prevention system rather than as a standalone intervention. Progress will depend on combining prevention choice with dependable testing, follow-up, community leadership, and stigma-sensitive communication. Regional and national differences require flexible implementation, while responsible use of data and AI can improve reach and continuity without compromising rights. Leaders that align clinical quality, affordability, privacy, and user choice can strengthen HIV prevention outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pre-Exposure Prophylaxis Market, by Product Type
7.1. Introduction
7.2. Branded
7.2.1. Descovy
7.2.2. Truvada
7.3. Generic
8. Pre-Exposure Prophylaxis Market, by Form
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Pre-Exposure Prophylaxis Market, by Distribution Channel
9.1. Introduction
9.2. Online Pharmacies
9.3. Offline Pharmacies
10. Pre-Exposure Prophylaxis Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care
10.4. Hospitals
11. Pre-Exposure Prophylaxis Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Pre-Exposure Prophylaxis Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Pre-Exposure Prophylaxis Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Accord Healthcare Inc.
15.2. Amneal Pharmaceuticals, Inc.
15.3. Aurobindo Pharma Ltd.
15.4. Cipla Ltd.
15.5. Dr. Reddy's Laboratories Ltd.
15.6. Fresenius Kabi AG
15.7. Gilead Sciences, Inc.
15.8. Hetero Labs Limited
15.9. Lupin Limited
15.10. Merck & Co., Inc.
15.11. Mylan N.V.
15.12. Sun Pharmaceutical Industries Ltd.
15.13. Teva Pharmaceutical Industries Ltd.
15.14. Viatris Inc.
15.15. ViiV Healthcare Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Pre-Exposure Prophylaxis Market, Years Considered for the Study
FIGURE 2. Global Pre-Exposure Prophylaxis Market, Research Design
FIGURE 3. Global Pre-Exposure Prophylaxis Market, Research Framework
FIGURE 4. Global Pre-Exposure Prophylaxis Market, Data Triangulation
FIGURE 5. Global Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Pre-Exposure Prophylaxis Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Pre-Exposure Prophylaxis Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Pre-Exposure Prophylaxis Market Size, by Form, 2025 vs 2032 (%)
FIGURE 9. Global Pre-Exposure Prophylaxis Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Pre-Exposure Prophylaxis Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Pre-Exposure Prophylaxis Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Pre-Exposure Prophylaxis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Pre-Exposure Prophylaxis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Pre-Exposure Prophylaxis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Pre-Exposure Prophylaxis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Pre-Exposure Prophylaxis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Pre-Exposure Prophylaxis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Pre-Exposure Prophylaxis Market Segmentation & Coverage
TABLE 2. Global Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Descovy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Descovy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Descovy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Truvada Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Truvada Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Truvada Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 17. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 24. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Offline Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Offline Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Offline Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 31. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 43. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 44. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. North America Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. North America Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 49. North America Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 50. North America Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 51. North America Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 52. North America Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Latin America Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Latin America Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 55. Latin America Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 56. Latin America Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 57. Latin America Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 58. Latin America Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. Europe Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Europe Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 61. Europe Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 62. Europe Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 63. Europe Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 64. Europe Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Middle East Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Middle East Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 67. Middle East Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 68. Middle East Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 69. Middle East Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Middle East Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Africa Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Africa Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. Africa Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 74. Africa Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 75. Africa Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Africa Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Global Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. ASEAN Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. ASEAN Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. ASEAN Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 81. ASEAN Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 82. ASEAN Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. ASEAN Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. GCC Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. GCC Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. GCC Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 87. GCC Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 88. GCC Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. GCC Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. European Union Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. European Union Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 92. European Union Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 93. European Union Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 94. European Union Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. European Union Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. BRICS Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. BRICS Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 98. BRICS Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 99. BRICS Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 100. BRICS Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. BRICS Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. G7 Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. G7 Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 104. G7 Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 105. G7 Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 106. G7 Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. G7 Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. NATO Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. NATO Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 110. NATO Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 111. NATO Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 112. NATO Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. NATO Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Global Pre-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. United States Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 116. United States Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. United States Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 118. United States Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 119. United States Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. United States Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. Canada Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 122. Canada Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. Canada Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 124. Canada Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 125. Canada Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. Canada Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. Mexico Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 128. Mexico Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 129. Mexico Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 130. Mexico Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 131. Mexico Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Mexico Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Brazil Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 134. Brazil Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 135. Brazil Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 136. Brazil Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 137. Brazil Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Brazil Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. United Kingdom Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 140. United Kingdom Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 141. United Kingdom Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 142. United Kingdom Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 143. United Kingdom Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. United Kingdom Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Germany Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 146. Germany Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. Germany Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 148. Germany Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 149. Germany Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. Germany Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. France Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 152. France Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 153. France Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 154. France Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 155. France Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. France Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Russia Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 158. Russia Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. Russia Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 160. Russia Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 161. Russia Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Russia Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Italy Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 164. Italy Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. Italy Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 166. Italy Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 167. Italy Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Italy Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Spain Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 170. Spain Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 171. Spain Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 172. Spain Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 173. Spain Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Spain Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. China Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 176. China Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. China Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 178. China Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 179. China Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. China Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. India Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 182. India Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 183. India Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 184. India Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 185. India Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. India Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Japan Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 188. Japan Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. Japan Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 190. Japan Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 191. Japan Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. Japan Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Australia Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 194. Australia Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 195. Australia Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 196. Australia Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 197. Australia Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Australia Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. South Korea Pre-Exposure Prophylaxis Market Size, 2017-2032 (USD Million)
TABLE 200. South Korea Pre-Exposure Prophylaxis Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. South Korea Pre-Exposure Prophylaxis Market Size, by Branded, 2017-2032 (USD Million)
TABLE 202. South Korea Pre-Exposure Prophylaxis Market Size, by Form, 2017-2032 (USD Million)
TABLE 203. South Korea Pre-Exposure Prophylaxis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. South Korea Pre-Exposure Prophylaxis Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Global Pre-Exposure Prophylaxis Market Share, by Key Player, 2025
TABLE 206. Global Pre-Exposure Prophylaxis Market, Key Experts

Companies Mentioned

  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited

Related Topics

Related Reports

Anti-Retroviral Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Retroviral Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Tenofovir Disoproxil Fumarate Tablets Market - Global Forecast 2026-2032 - Product Image

Tenofovir Disoproxil Fumarate Tablets Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Anti-Retroviral Drugs - Global Strategic Business Report - Product Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026 - Product Image

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis - Update - Product Image

Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis - Update

  • Report
  • 177 Pages
  • Global
From

About the Pre Exposure Prophylaxis Market

Pre Exposure Prophylaxis (PrEP) is a form of HIV prevention that involves taking a daily pill to reduce the risk of HIV infection. PrEP is a combination of two antiretroviral drugs, tenofovir and emtricitabine, which are used to treat HIV. PrEP is recommended for people who are at high risk of HIV infection, such as men who have sex with men, transgender women, and people who inject drugs. PrEP is highly effective in preventing HIV infection when taken as prescribed. PrEP is available in many countries around the world, and is becoming increasingly accessible. PrEP is typically prescribed by a healthcare provider and is available in both generic and branded forms. The cost of PrEP varies depending on the country and the type of drug prescribed. Several pharmaceutical companies are involved in the PrEP market, including Gilead Sciences, Mylan, and Teva Pharmaceuticals. Gilead Sciences is the largest manufacturer of PrEP drugs, with its branded drug Truvada being the most widely used PrEP drug. Mylan and Teva Pharmaceuticals also produce generic versions of PrEP drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.